AN UNUSUAL REACTION TO ETOPOSIDE

[1] CREAVEN PJ, 1974, CANCER CHEMOTH REP 1, V58, P901

[2] DORR RT, 1980, CANCER CHEMOTHERAPY, P420

[3] JACOBS P, 1975, S AFR MED J, V49, P483

[4] JUNGI WF, 1975, CANCER CHEMOTH REP 1, V59, P737

[5] MCEVOY GK, 1988, AM HOSPITAL FORMULAR, P510

[6] ODWER PJ, 1984, CANCER TREAT REP, V68, P859

[7] ROZENCWEIG M, 1977, CANCER, V40, P334, DOI 10.1002/1097-0142(197707)40:1<334::AID-CNCR2820400147>3.0.CO

[8] 2-X

[9] HIGH-DOSE VP-16-213 AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR REFRACTORY MALIGNANCIES - A PHASE-I STUDY [J]. JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) : 701 - 705

[10] 1973, BRIT MED J, V3, P199

[1] CREAVEN PJ, 1974, CANCER CHEMOTH REP 1, V58, P901

[2] DORR RT, 1980, CANCER CHEMOTHERAPY, P420

[3] JACOBS P, 1975, S AFR MED J, V49, P483

[4] JUNGI WF, 1975, CANCER CHEMOTH REP 1, V59, P737

[5] MCEVOY GK, 1988, AM HOSPITAL FORMULAR, P510

[6] ODWER PJ, 1984, CANCER TREAT REP, V68, P859

[7] ROZENCWEIG M, 1977, CANCER, V40, P334, DOI 10.1002/1097-0142(197707)40:1<334::AID-CNCR2820400147>3.0.CO

[8] 2-X

[9] HIGH-DOSE VP-16-213 AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR REFRACTORY MALIGNANCIES - A PHASE-I STUDY [J]. JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) : 701 - 705

[10] 1973, BRIT MED J, V3, P199